Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Items 801–900 of 1,004
Spakowicz, D. J., Bibi, A., Muniak, M., Williams, N. F., Hoyd, R., & Presley, C. J. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.02.001 · Cited by 8
Nakatsu, G. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15715 · Cited by 10
Cheng, C., Yin, Y., & Bian, G. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1018284 · Cited by 9
“Genera Colidextribacter has been reported to reduce tissue damage and inflammation through modulating signaling pathways (Mager et al., 2020; Guo et al., 2021).”
BackgroundTargeting microbiome, drug metabolism, and drug delivery in oncology
Sumiyoshi, A., Fujii, H., & Okuma, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114902 · Cited by 9
Interaction of microbiota, mucosal malignancies, and immunotherapy—Mechanistic insights
Mager, L. F., Krause, T., & McCoy, K. D. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.03.007 · Cited by 8
Self-citationMicrobiome‐driven anticancer therapy: A step forward from natural products
Guan, Y., Wu, D., Wang, H., & Liu, N. (2024) · mLife · doi:10.1002/mlf2.12118 · Cited by 8
Applying metabolic control strategies to engineered T cell cancer therapies
Fox, A., & Blazeck, J. (2024) · Metabolic Engineering · doi:10.1016/j.ymben.2024.10.009 · Cited by 7
Gut microbiome signature in response to neoadjuvant chemoradiotherapy in patients with rectal cancer
Duan, T., Ren, Z., Jiang, H., Yan, D., Wang, H., & Wang, F. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1543507 · Cited by 7
“Notably, previous studies have demonstrated that species such as Bifidobacterium pseudolongum , Lactobacillus johnsonii , and members of the Olsenella genus significantly enhance the efficacy of immune checkpoint inhibitors (Mager et al., 2020).”
Qiu, X., Gao, Q., Wang, J., Zhang, Z., & Tao, L. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189317 · Cited by 11
Nervous system–gut microbiota–immune system axis: future directions for preventing tumor
Wang, J., Cheng, W., & Yang, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1535955 · Cited by 11
Nieves, L. M., Roach, A., Hunter, J., Smeh, S., Islas, A., Islas, A. K. F., Blattman, J. N., & DiPalma, M. P. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1577108 · Cited by 7
Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
Hu, J., Feng, T., Zhang, L., Zhou, Q., & Zhu, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003687 · Cited by 8
Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk
Buzhor, M. G., Longobardi, G., Kandli, O., Krinsky, A., Avramoff, O., Katyal, A., Salomon, K., Miari, A., Venkert, D., Barnatan, T. T., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503198 · Cited by 12
Wu, D., Zhang, F., Wang, H., Xie, L., Liu, B., Xiao, S., Chen, W., Ye, Y., Chen, Z., Shui, G., et al. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2943-4 · Cited by 7
“It can be produced by beneficial bacteria like Bifidobacterium pseudolongum and A . muciniphila (Mager et al., 2020) and even by host cells like apoptotic brown adipocytes, where it stimulates energy expenditure (Brown et al., 2021; Niemann et al., 2022).”
Wang, F., Fan, J., Pan, W., Liu, M., Wang, J., Wei, X., Xian, Y., Chen, S., Cui, C., Chen, Y., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.10.012 · Cited by 14
Jiang, T., Li, C., Pan, Z., Wang, Y., Chen, X., Song, J., Zhu, K., Yang, Y., Hou, Y., Sun, L., et al. (2025) · Diabetes · doi:10.2337/db25-0471 · Cited by 7
Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics
Wei, D., Sun, Y., Han, J., & Liu, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.002 · Cited by 9
Yoon, S. E., Kang, W., Cho, J., Cho, H. J., Chalita, M., Oh, H., Hyun, D., Han, S. H., Kim, H., Sung, H., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016858 · Cited by 7
“19,20 Microbiome-derived inosine activates T cells via the adenosine A2A receptor, bolstering antitumor immunity.”
Microbial-Derived Metabolites and Their Impact on Cancer Immunotherapy
Jeong, J., Baines, K. J., & Vareki, S. M. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-1018 · Cited by 9
Gut microbiota drives cancer evolution and therapy resistance
Min, S., Zhang, Y., Zhang, H., & Liu, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02564-8 · Cited by 10
“Additionally, it engages the adenosine A2A receptor on T cells to further enhance the sensitivity to ICI [212].”
Yang, J., Dai, Y., & Li, J. (2026) · Oncology Reviews · doi:10.3389/or.2025.1687901 · Cited by 9
“…responses (84); secondary bile acids upregulate the number of CXCR6 + NKT cells through enterohepatic circulation to strengthen innate immune surveillance (99); and inosine produced by Lactobacillus johnsonii activates Th1 cells via A2AR signaling, synergizing with immune checkpoint blockade (100).”
Setting higher standards for reports of microbial species in human cancers
Salzberg, S. L., Chia, M., Tay, C. Y., de Miranda, N. F. C. C., Smit, V. T. H. B. M., Wesseling, J., Irizarry, R. A., Marshall, B. J., Willerslev, E., Neefjes, J., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01121-6 · Cited by 8
Feng, C., He, Q., Kwok, L. Y., & Sun, Z. (2026) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2026.105818 · Cited by 8
Diet–microbiome synergy underlies obesity-associated immunotherapy efficacy
Desharnais, L., Swaby, A. M., Messaoudene, M., Doré, S., Yu, M. W., Fiset, B., Breton, V., Ponce, M., Hu, Y., Wilson, L., et al. (2026) · Nature · doi:10.1038/s41586-026-10750-x · Cited by 9
“We identified L. johnsonii as one of several key species associated with anti-PD-1 response, consistent with prior reports linking Lactobacillus with checkpoint blockade efficacy 38,52,53 .”
Raman, M., Ma, C., Taylor, L. M., Dieleman, L. A., Gkoutos, G. V., Vallance, J. K., McCoy, K. D., Lewis, I., Jijon, H. B., McKay, D. M., et al. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000841 · Cited by 8
Self-citationThe Urogenital System’s Role in Diseases: A Synopsis
Zerdan, M. B., Moukarzel, R., Naji, N. S., Bilen, Y., & Nagarajan, A. (2022) · Cancers · doi:10.3390/cancers14143328 · Cited by 8
“pseudolongum, improved response to targeted immunotherapy, anti-CTLA-4 in particular [21].”
BackgroundThe complex immunological role of Helicobacter in modulating cancer
Hand, T. W., & Overacre-Delgoffe, A. E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.08.002 · Cited by 10
Prospect of research hotspots in prevention and treatment of diseases based on intestinal microbiome
Cai, Y., Zhang, Y., Wang, W., & Geng, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.971457 · Cited by 7
“According to a study, in four mouse models of cancer, the researchers isolated three bacteria species that produce inosine– Bifidobacterium pseudolongum, Lactobacillus Johnsonii and Olsenella, which noteworthy increased the efficacy of checkpoint inhibitor immunotherapy (2).”
BackgroundRational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies
Cox, J. R., Jennings, M. R., Lenahan, C., Manion, M., Courville, S., & Blazeck, J. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100394 · Cited by 9
“More recently, inosine has been also shown to have a role in proinflammatory T-cell effector functions by supporting TH1 cell differentiation during activation.(23) In addition, inosine (but not adenosine) can serve as an alternative carbon source for glucose-restricted T cells in tumors.”
BackgroundPandey, A., Lieu, C. H., & Kim, S. S. (2023) · Cancers · doi:10.3390/cancers15143562 · Cited by 8
“Certain commensal bacteria synthesize the metabolite inosine, which may enhance the efficacy of ICI therapy [49].”
BackgroundWang, X., Guo, C., Xu, X., Zhang, L., Li, S., Dai, D., & Du, W. (2023) · Fermentation · doi:10.3390/fermentation9110973 · Cited by 7
Zou, L., Mo, S., Jia, C., Pang, J., Chang, X., & Chen, J. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16437 · Cited by 7
“18 22 Interestingly, our study found that Bifidobacterium might play a role in reducing cancer invasiveness because those with a higher relative abundance of Bifidobacterium had a signi fi cantly lower proportion of neural or lymphovascular invasion than those with a lower relative abundance.”
BackgroundZhang, P., Xu, J., & Zhou, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1357261 · Cited by 8
“…(Duncan et al., 2002; Vacca et al., 2020), Coprococcus (Rogosa, 1969; Vacca et al., 2020), Megamonas (Bishehsari et al., 2018), Alloprevotella (Bishehsari et al., 2018), and Acidaminococcus (Bishehsari et al., 2018; Mager et al., 2020) are producers of SCFAs such as acetic acid and propionic acid.”
BackgroundResultInfluentialIntratumoral Microbiota: Insights from Anatomical, Molecular, and Clinical Perspectives
Lombardo, C., Fazio, R., Sinagra, M., Gattuso, G., Longo, F., Lombardo, C., Salmeri, M., Zanghì, G., & Loreto, C. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14111083 · Cited by 8
Non-coding RNAs in bladder cancer, a bridge between gut microbiota and host?
Zou, J., Xu, B., Luo, P., Chen, T., & Duan, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1482765 · Cited by 9
Gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses
Gutzeit, C., Grasset, E. K., Matthews, D. B., Maglione, P. J., Britton, G. J., Miller, H., Magri, G., Tomalin, L. E., Stapylton, M., Canales-Herrerías, P., et al. (2025) · Science Advances · doi:10.1126/sciadv.ado9455 · Cited by 8
“The gut microbiota restrains signaling from PD-1 via ino-sine, a metabolite that modulates T cells through the adenosine A 2A receptor ( 63 ).”
Grant, N. A., Donkor, G. Y., Sontz, J. T., Soto, W., & Waters, C. M. (2025) · mBio · doi:10.1128/mbio.00036-25 · Cited by 8
“Recent studies have demonstrated that various spe cies of gut bacteria, including Lactobacillus (44) and Bifidobacterium (45), secrete inosine in significant quantities during growth.”
Unveiling the microbial influence: bacteria’s dual role in tumor metastasis
Lin, L.-Y., & Zhang, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1524887 · Cited by 9
“For instance, speci fi c bacterial taxa, such as Bi fi dobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species, have been demonstrated to enhance the ef fi cacy of ICPIs, facilitating improved recognition and destruction of cancer cells by the immune system (85).”
Li, M., Ye, G., Liu, Y., Yang, T., Zhao, B., Jiang, R., & Chen, G. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118229 · Cited by 7
Microbiota mechanisms in cancer progression and therapy
Zhang, X., Fam, K. T., Dai, T., & Hang, H. C. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.005 · Cited by 9
Gubert, C., Kong, G., Shadani, S., Connell, S., Masson, B. A., van de Garde, N., Narayana, V. K., Renoir, T., & Hannan, A. J. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf056 · Cited by 9
Naz, F., & Arish, M. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15315 · Cited by 7
“A recently published paper showed that bacterial-derived metabolite inosine, can promote Th1 cell activation via adenosine 2A (A2) receptor, a GPCR enhancing anti-tumour immunity (Mager et al., 2020).”
BackgroundThe nature of triple-negative breast cancer classification and antitumoral strategies
Kim, S., Kim, D. H., Lee, W., Lee, Y., Choi, S., & Han, K. (2020) · Genomics & Informatics · doi:10.5808/gi.2020.18.4.e35 · Cited by 9
“Inosine binding to T cell–specific adenosine 2A receptor (A2AR) promotes Th1 cell activation [30].”
BackgroundHilakivi-Clarke, L. A., Verma, V., McDermott, M., Koak, P., & Andrade, F. D. O. (2022) · Frontiers in Microbiomes · doi:10.3389/frmbi.2022.1049688 · Cited by 7
Advances in Organoid Culture Research
Xie, Z., Wang, L., & Zhang, Y. (2022) · Global Medical Genetics · doi:10.1055/s-0042-1756662 · Cited by 10
Hirata, M., Matsuoka, M., Hashimoto, T., Oura, T., Ohnuki, Y., Yoshida, C., Minemura, A., Miura, D., Oka, K., Takahashi, M., et al. (2022) · Microbes and Environments · doi:10.1264/jsme2.me22011 · Cited by 7
Microbes and vitamin D aid immunotherapy
Franco, F., & McCoy, K. D. (2024) · Science · doi:10.1126/science.adp1309 · Cited by 7
Self-citationMa, W., Li, Y., Hu, Y., Liu, X., Guo, Z., Zhong, B., Qiu, H., & Li, J. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1482925 · Cited by 12
PCV2 infection induces the differentiation of Treg cells via the TGF-β/Smad3 pathway
Jiang, R., Huang, Q., Shen, R., Zhang, Y., Zhou, L., Ge, X., Han, J., Guo, X., & Yang, H. (2025) · mBio · doi:10.1128/mbio.01366-25 · Cited by 8
“Notably, several species of intesti nal bacteria, such as Lactobacillus , have been associated with enhanced efficacy of checkpoint blockade immunotherapy (46).”
Intratumoral microbial heterogeneity in HCC reveals a potential therapeutic target
Li, L., Wang, M., Jiang, Z., Yi, C., & Yi, Y. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101538 · Cited by 7
“37 This mechanism significantly enhances the antitumor effects of Th1 cells in various cancers including melanoma, bladder cancer, and colorectal cancer.”
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future
Luo, H.-Y., Cao, L., Zhou, K., Xiao, Y., Li, Z., Liu, B., & Bu, L. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.08.001 · Cited by 6
Assessment of probiotic and prebiotic use in gynecologic cancer patients: a systematic review
Chalif, J., Morton, M. A., Haight, P. J., Mehra, Y., O’Malley, D. M., Spakowicz, D. J., & Chambers, L. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.09.042 · Cited by 6
Inosine: biofunctions and the roles in human diseases
Li, F., Zhang, J., Kang, J., Tong, X., Zhang, P., & Zhu, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1634814 · Cited by 9
Research progress on gut microbiota in colorectal cancer immunotherapy
Li, J., Yue, Y., Pan, J., & Liang, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189476 · Cited by 7
Destruction of VISTA by TRIM25 ablation in T cells potentiates cancer immunotherapy
Sun, Y., Zhang, Z., Li, H., Bu, X., Chen, L., Wang, X., Fan, L., Chen, B., Kong, L., Dai, P., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01186-5 · Cited by 7
Yuan, S., Bremmer, A., Yang, X., & Hu, Q. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.11.023 · Cited by 8
Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy
Lu, Q., Wu, J., Yu, X., Qian, J., & Song, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690374 · Cited by 6
Gut microbe alleviates stress-related cancer metastasis by oleic acid degradation
Liu, C., Gong, J., Luo, Z., Lai, P., Guo, S., Liang, D., Chen, G., Xing, M., Yu, J., Xie, Y., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-335627 · Cited by 9
“For instance, microbiome-derived inosine affects the response to checkpoint inhibitor immunotherapy, 40 while microbiome-derived adenosine promotes cancer development.”
Sang, T., Xu, T., Chen, C. Y., Wu, J., Zhou, C., Li, F., Xu, L., Liu, S., Wang, M., Zhang, Y., et al. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c12282 · Cited by 8
Rukonge, P. A., Kawuribi, V., Sheng, Y., Wei, Q., Kun, Y., Niyodukunda, P., Wang, T., Lu, Z., Miao, Y., Xu, K., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105094 · Cited by 9
Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation
Majumder, B., & Datta, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1676702 · Cited by 9
“INO, derived from the microbiome, can boost ICB response in an A2AR-pro fi cient environment (73), indicating critical competitive roles of this metabolite (Figure 2).”
Lou, S., Li, W., Wang, G., Qian, H., & Zhou, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105217 · Cited by 9
Hsu, C.-Y., Almajidi, Y. Q., Abohassan, M., Refatovich, G. R., Basunduwah, T. S., Hjazi, A. M., Arora, V., Nayak, P. P., Shukla, S. K., & Jayabalan, K. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105229 · Cited by 6
Kapoor, A., Gupta, A., Sansar, B., Mishra, B. K., Kallapura, G., Giridhar, P., & Kumar, R. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00194 · Cited by 6
Chen, Y., Wang, Y., Hu, J.-Y., Wang, E.-C., Jia, X.-H., Wang, J., Min, G., Jin, W.-L., & Jiang, L. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2652476 · Cited by 8
“56,57”
The Intestinal Microbiota and Therapeutic Responses to Immunotherapy
Herrera, P. S., & van den Brink, M. R. M. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-035210 · Cited by 6
Sepulveda, M., Rasic, M., Lei, Y. M., Kwan, M., Chen, L., Chen, Y., Perkins, D. L., & Alegre, M. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.03.020 · Cited by 6
An overview on recent approaches for colonic drug delivery systems
Ghodratı, A. D., & Çomoğlu, T. (2024) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2024.2362353 · Cited by 10
“…that can metabolize drugs and change their pharmacokinetics, which can either improve or worsen clinical response when treating systemic illnesses like Human Immunodeficiency Viruses (HIV), Parkinson’s disease, celiac disease, and diabetes mellitus (Hatton et al. 2019; Mager et al. 2020).”
Katsurayama, N., Ishihara, H., Ishiyama, R., Nemoto, Y., Ikeda, T., Mizoguchi, S., Nakayama, T., Fukuda, H., Yoshida, K., Iizuka, J., et al. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10354 · Cited by 6
Guo, Z., Lei, Y., & Wang, Q. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12692 · Cited by 7
“A further metagenomic study revealed functional differences in gut bacteria in treatment responders, including enrichment in anabolic pathways (26).”
BackgroundMinervini, G., Shivakumar, S., Ronsivalle, V., Franco, R., Cicciù, M., & Marrapodi, M. M. (2024) · Dental and Medical Problems · doi:10.17219/dmp/183712 · Cited by 13
“36 This phenomenon is often observed in the context of leaky gut syndrome, where the integrity of the intestinal bar rier is compromised.”
Melatonin Sources in Sheep Rumen and Its Role in Reproductive Physiology
Niu, T., Ding, Z., Zeng, J., Yan, Z., Duan, H., Lv, J., Zhang, Y., Zhang, L., & Hu, J. (2024) · Animals · doi:10.3390/ani14233451 · Cited by 6
Gui, W., Yin, J.-G., Liao, J.-C., Luo, H.-Z., You, Q., Gong, J., Xiang, J., Zou, J., & Li, C. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01045-2 · Cited by 6
Yao, W., Du, R., Yan, S., Bao, T., Zhang, H., Yang, F., Xue, Y., Zhao, Y., Bao, S., Li, X., et al. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106691 · Cited by 7
Hamza, M., Wang, S., Liu, Y., Li, K., Zhu, M., & Chen, L. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128156 · Cited by 6
Kolland, D., Kuhlmann, M., de Almeida, G. P., Köhler, A., Arifovic, A., von Strempel, A., Pourjam, M., Bolsega, S., Wurmser, C., Steiger, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59073-x · Cited by 7
“It is tempting to investigate the function of the microbiome or the metabolites they produce also directly on the differentiation and effector function of Th1 cells present in tumors 77 .”
Roseburia intestinalis Modulates Immune Responses by Inducing M1 Macrophage Polarization
Bircher, A., Katkeviciutė, E., Morsy, Y., Lang, S., Montalban‐Arques, A., & Scharl, M. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115049 · Cited by 6
“In fact, recent studies have shown that specific members of the gut microbiota are able to increase the efficacy of immune checkpoint inhibitor (ICI) immunotherapy in different types of cancers, such as melanoma, sarcoma or CRC [17–21].”
Wang, X., Ma, L., Wang, Y., Xu, J., Long, J., Ju, X., Qu, Y., Mayo, K. H., Zhou, Y., Sun, L., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145361 · Cited by 6
Al-Khazaleh, A. K., Alsherbiny, M. A., Münch, G. W., Chang, D., & Bhuyan, D. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146829 · Cited by 8
“Among the most studied postbiotics are inosine, Nisin (N), Urolithin A (UA), Urolithin B (UB), and short-chain fatty acids (SCFAs), which have shown potential therapeutic benefits in various cancer models [14–17].”
Research Progress in Intestinal Microecology in Pancreatic Cancer Diagnosis and Treatment
Han, Z., Zhang, H., Lu, L., Li, X., Zhang, C., Zhu, J., Li, C., Wang, Q., & Chen, K. (2022) · Journal of Oncology · doi:10.1155/2022/6069403 · Cited by 6
“Tey can enhance the expansion of regulatory T cells (Treg cells) and improve the function of efector Tcells.”
BackgroundThe Role of the Microbiome in Erectile Dysfunction
Leelani, N., Bole, R., Khooblall, P., Bajic, P., & Lundy, S. D. (2023) · Current Sexual Health Reports · doi:10.1007/s11930-023-00365-y · Cited by 7
Commensal bacteria and cancer immunotherapy: strategy and opportunity
Zhang, X., Qin, X., & Wang, S. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad024 · Cited by 8
Factors of faecal microbiota transplantation applied to cancer management
Liu, Y.-H., Chen, J., Chen, X., & Liu, H. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2023.2299724 · Cited by 6
“…resistance and antitumor effects and even reduced drug resistance and fewer adverse events than hosts with unfavourable microbiota or hosts lacking microbiota diversity [25,37,45]. these two adverse microbiota states can be changed with faecal transplantation to alter the gut microbiota.”
BackgroundYu, Y., Ren, X., Cao, L., Liang, Q., Xiao, M., Cheng, J., Nan, S., Zhu, C., Kong, Q., Fu, X., et al. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15730 · Cited by 9
“Mager et al. (2020) also found the immunity improvement ability of B. pseudolongum, which enhanced the efficacy of ICB therapy in mouse models of cancer.”
BackgroundInfluentialModulation of myeloid cells by adenosine signaling
Cekic, C. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.012 · Cited by 6
Almonte, A. A., Cavic, G., Neeman, T. M., Enders, A., & Fahrer, A. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005575 · Cited by 8
DNA-utilization loci enable exogenous DNA metabolism in gut Bacteroidales
Sharan, D., Nurek, A., Stemczynski, J., Turan, K., Little, A. S., Coyne, M. J., McMillin, M., Sidebottom, A. M., Comstock, L. E., & Light, S. H. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2505388122 · Cited by 5
“Microbiome - derived nucleosides inosine and guanosine modulate immune function, enhancing cancer immunotherapy outcomes and promoting tolerance against food allergens, respectively ( 10 , 11 ).”
Bian, M., Ji, J., Lian, N., Li, Y., Zhu, W., Cao, P., & Zhang, F. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157309 · Cited by 5
Zhou, Z., Lin, J.-R., Li, J., Huang, X., Lu, Y., Huang, J., Xie, W., Lu, J., Huang, W., He, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012444 · Cited by 6
Zhu, C., Huai, Q., Du, Y., Li, X., Zhang, F., Zhang, Y., Wu, M., Dai, Y., Li, X., Dai, H., et al. (2025) · MedComm · doi:10.1002/mco2.70445 · Cited by 7
Mechanism of anticancer action of bifidobacterium : Insights from gut microbiota
Do, H., Asiamah, E., Olorife, M., Pillai, A., Patel, S., Selvakumar, P., Ray, S. D., & Lakshmikuttyamma, A. (2025) · Oncotarget · doi:10.18632/oncotarget.28779 · Cited by 6
“Furthermore, this study found that the concentration of a microbial metabolite inosine was significantly higher in Bifidobacterium. pseudolongum monocolonized colorectal cancer mice model compared with colidextribacter species monocolonized mice [66].”
InfluentialZheng, M., Meng, Y., Feng, J., Liang, H., Mu, X., & Feng, C. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157559 · Cited by 5
Toumazi, D., Charalambous, C., Constantinou, C., & Nicolaou, N. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf267 · Cited by 5
Zhai, Z., Li, X., Shang, S., Ma, S., Liang, X., Yin, S., Wu, M., Yu, J., Song, Q., & Chen, D. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-025-02623-z · Cited by 5
“In a melanoma mouse model, the concurrent use of inosine and anti-PD-1 antibody treatment retards tumor expansion and increases patients’ OS [138].”
Liu, Q., Liu, Y., Zhou, Y., Liang, L., Wan, Y., Wang, Y., Huang, T., Zhong, L., Li, Z., Luo, T., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-0346 · Cited by 6
Spatial profiling of the metabolism-immune axis in ovarian cancer
Wang, Z.-B., Long, M., Yu, P., Wang, Y., Yang, Z., & Huang, M.-S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1672020 · Cited by 11
Yang, X., Zhang, K., Xia, L., & Li, J. (2026) · iMetaMed · doi:10.1002/imm3.70030 · Cited by 5
Lobel, L., Fonseca‐Pereira, D., Nakatsu, G., Michaud, M., Cao, Y. G., Bae, S., Krabak, C., Oren, Y., Clay, S. L., Tekle, G. E., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.05.001 · Cited by 6
Guo, X., Wei, Y., Miao, Z., Ma, S., & Ma, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924506 · Cited by 6
“The gut microbiome may in fl uence systemic responsiveness to PD-1/PD-L1 blockade through microbial products that enter the circulation and modulate antigen-presenting cells, T-cell metabolism, and in fl ammatory signaling (182, 183).”
How do tumours outside the gastrointestinal tract respond to dietary fibre supplementation?
Asim, F., Clarke, L., Donnelly, E., Jamal, F. R., Piccicacchi, L. M., Qadir, M., Raja, N. T., Samadi, C., Then, C. K., & Kiltie, A. E. (2023) · BMJ Oncology · doi:10.1136/bmjonc-2023-000107 · Cited by 5
“81 Additionally, the gut bacteria-produced inosine from dietary barley leaf supplementation mitigated perturbation of gut microbiota and dextran sulfate sodium-induced colitis, 80 implying the A recent study by Spencer et al reported that in a cohort of 128 patients undergoing anti- PD-1 therapy,…”
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.